2cureX, Germany receives an additional grant for adapting IndiTreat® to guide immunotherapy of ovarian cancer patients

Copenhagen – April 6, 2020 – 2cureX AB (“2cureX”, NASDAQ: 2CUREX) announced today that 2cureX’s German subsidiary 2cureX GmbH (“2cureX”) has received another grant from the German Federal Ministry of Education and Research to adapt  the company´s  IndiTreat® test for individualizing immunotherapy for patients suffering from ovarian cancer. This project is conducted in collaboration with the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Hamburg-Eppendorf, “UKE”).

In January 2017 2cureX and UKE were granted net 810.216 EUR to adapt the IndiTreat® test to ovarian cancer and to predict immunotherapy drug responses in patients suffering from colorectal cancer. This work has progressed very satisfactorily and the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) has now decided to endorse the project with an additional grant of 1.322.520 EUR with the intention that the method can benefit the patients faster. 2cureX will receive 553.280 EUR.

Because of its success in various solid cancers, immunotherapy is the fastest growing treatment approach in oncology. However, clinical evidence is accumulating that immunotherapy often needs to be combined with other drug modalities to improve the long-term treatment outcome for patients.

Ovarian cancer kills more than 40.000 women in Europe every year due to lack of effective and long-lasting therapeutic regimens. Nearly all patients become resistant to their initial treatment and more than half die within five years after diagnosis.

IndiTreat®, a Functional Precision Medicine test, will be able to measure the efficacy of both existing and novel immunotherapies alone or in combination with other cancer drugs thus providing an effective means to improve the overall outcome of ovarian cancer patients.

Jürgen Kupper, Managing Director, 2cureX GmbH says: “2cureX’s efforts to expand the capabilities of IndiTreat® to guide treatment of cancer patients is critically dependent upon active collaborations with world class clinical institutions. It is therefore with excitement that we now can strengthen our year-long collaboration with UKE to finalize the IndiTreat® test for immunotherapy in ovarian cancer patients.”

Jasmin Wellbrock, Oncology Research Leader, UKE says: “Although no immuno-oncological treatment has been approved for ovarian cancer so far, several candidates are in late clinical study phases. As we have seen with other cancer entities, we expect to see a large variation in how different patients respond to immunotherapy.”  Leticia Oliveira-Ferrer, Oncology Research Leader, UKE adds: “I see that Functional Precision Medicine tests could become an important tool for oncologists when identifying the patients that are sensitive to the new immunotherapy treatments.”

For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com

Certified Adviser:
Svensk Kapitalmarknadsgranskning AB
Email: ca@skmg.se
Phone: +46 11 32 30 732

This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 6, 2020.

-------

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumours that are similar to the patient’s tumour and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

IndiTreat® is presently being introduced into the European market through an Early Access Program. 

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).

About Us

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients. IndiTreat® is currently being clinically validated in colorectal and ovarian cancer. The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).

Subscribe

Media

Media

Documents & Links